Press Releases
WALTHAM, Mass., Sep 19, 2011 (BUSINESS WIRE) --
NeuroMetrix, Inc. (Nasdaq: NURO) today reported the initiation of commercial shipments of NC-stat® DPNCheck, a fast, accurate and quantitative point-of-care test for the evaluation of systemic neuropathies such as diabetic peripheral neuropathy (DPN). DPN affects more than half of people with diabetes and may lead to foot ulcers and limb amputation, as well as pain and an overall reduction in quality of life. NeuroMetrix believes that the NC-stat DPNCheck test may address the unmet medical need for better, cost-effective approaches to detecting and monitoring DPN.
The NC-stat DPNCheck device measures sural nerve conduction velocity and amplitude which are recognized early and quantitative biomarkers for DPN. Commercial shipment represents the culmination, on schedule, of a year-long product development effort to modify the Company's NC-stat technology to the focused evaluation of the sural nerve. In tandem, the development effort resulted in substantial cost reductions that enable an innovative approach to commercial deployment of this important advance in diabetes care. Initial shipments of NC-stat DPNCheck are being made primarily to endocrinologists and podiatrists who have elected a 30 day product evaluation to assess its relevance to diabetes management in their practice. Product training and support is being provided by the eight person NeuroMetrix specialty sales team.
About NeuroMetrix
NeuroMetrix is a science-based health care company improving patient care through neurotechnology. The company develops and markets innovative products for the detection, diagnosis, and monitoring of peripheral nerve disorders such as those associated with diabetes and carpal tunnel syndrome. For more information, please visit http://www.neurometrix.com.
Safe Harbor Statement
The statements contained in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the company's or management's expectations, hopes, beliefs, intentions, or strategies regarding future developments and their potential effects on the company. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "plan," "hope" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. While the company believes the forward-looking statements contained in this press release are accurate, there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. There can be no assurance that future developments will be those that the company has anticipated. The forward-looking statements contained in this press release include, but are not limited to, those that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the company's most recent annual reports as well as other documents that may be filed from time to time with the Securities and Exchange Commission or otherwise made public. The company is providing the information in this press release only as of the date hereof, and expressly disclaim any intent or obligation to update the information included in this press release or revise any forward-looking statements.
SOURCE: NeuroMetrix, Inc.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
Chief Financial Officer
neurometrix.ir@neurometrix.com